Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 19, 2026
The TimesSquare U.S. Mid Cap Growth Strategy returned -5.70% net of fees in the third quarter of 2026, outperforming the Russell Midcap Growth Index return of -5.84%. Year-to-date, the strategy has gained 2.86% net of fees compared to 1.01% for the benchmark. Relative outperformance was primarily driven by positive stock selection within Consumer Discretionary (+1.15% active contribution) and Health Care (+0.40%), alongside an underweight in Communication Services (+0.28%). These gains were partially offset by positioning headwinds in Industrials (-0.37%), Financials (-0.36%), and Energy (-0.33%). Cash exposure remained neutral, and the portfolio maintained full equity investment across its diversified sector allocations. Macroeconomic conditions were defined by a Federal Reserve rate hike of 25 basis points to 3.75%-4.00%, rising Treasury yields, and escalating oil prices due to unresolved U.S.-Iran conflict. Despite persistent economic expansion across services and manufacturing, market breadth narrowed substantially, penalizing high-momentum growth assets and heavily favoring companies with lower financial leverage and higher profitability. Key portfolio transactions included trimming top performers Veeva Systems ($VEEV) following substantial price appreciation, and initiating new positions in optical networking supplier Lumentum Holdings ($LITE) and high-speed connectivity provider Credo Technology ($CRDO). Conversely, the strategy completely exited Regal Rexnord ($RRX) to rotate capital into RBC Bearings ($RBC), and liquidated Ionis Pharmaceuticals ($IONS) after two late-stage Phase 3 pipeline setbacks.
The strategy invests in mid-capitalization growth companies possessing quality management, distinct competitive advantages, and strong, sustainable growth characteristics while maintaining disciplined valuation sensitivity.
The investment team remains committed to a disciplined quality-growth orientation entering the fourth quarter, selectively evaluating early artificial intelligence infrastructure adoption while remaining cautious on expensive multiples, rising input costs, and vulnerable software models.
Neutral / Balanced
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with TimesSquare Capital Management U.S. Mid Cap Growth Strategy or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.